By PTI Jul 14, 2020 10:59:01 AM IST (Updated)
Cipla's Icatibant injectable pre-filled syringe in the strength of 30mg/3mL is generic version of Shire's Firazyr, the company said in a regulatory filing.
Drug major Cipla on Tuesday said it has received final approval from the United States Food and Drug Administration (USFDA) for Icatibant Injectable, indicated for treatment of acute attacks of hereditary angioedema - a rare genetic condition - in adults.
Recommended Articles
View All
New Locker Rules — Here's why the RBI has gone overboard
Jan 28, 2023 IST5 Min(s) Read
Meet Padma Shri Awardee Guru K Kalyanasundaram Pillai, the man who is keeping an ancient tradition alive
Jan 27, 2023 IST3 Min(s) Read
This is how the new draft IT rules propose to make online gaming safe
Jan 27, 2023 IST4 Min(s) Read
Rs 11 lakh crore market cap lost in biggest two-day fall in four months
Jan 27, 2023 IST3 Min(s) Read
Cipla's Icatibant injectable pre-filled syringe in the strength of 30mg/3mL is generic version of Shire's Firazyr, the company said in a regulatory filing. The firm said "it has received final approval for its abbreviated new drug application for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration".
Quoting IQVIA (IMS Health) data, Cipla said Firazyr and its generic equivalents had US sales of approximately USD 270 million for the 12-month period ending May 2020.
Shares of Cipla were trading 0.49 percent higher at Rs 641.25 apiece on the BSE.
First Published: Jul 14, 2020 10:57 AM IST
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!